Atlas Antibodies has released novel monoclonal antibodies for female genital tract pathology

Our company has now released new PrecisA Monoclonal^TM antibodies targeting 23 proteins relevant to ovarian cancers, with diagnostic and prognostic values validated in IHC, WB and ICC-IF.

Ovarian cancer is the 8^th most common cancer among women and the 5^th cause of cancer-related death in women with a 5-year survival of only 30–50%. It still remains the deadliest gynecologic malignancy in the western world and is most often diagnosed at a rarely curable late stage.

>>>Download Ovarian cancer Infographic

Early detection of ovarian cancer would in fact improve the 5-year survival rate, from 20% when the cancer is discovered in stage IV to 90% in stage I.

>>>Find the right primary antibody for your research and order here online.

The primary tumor biopsy followed by immunohistochemical analysis (IHC) of the tissue remains the gold standard to identify the molecular alterations associated with the tumors and identify potential prognostic and predictive biomarkers for early-stage detection.

Atlas Antibodies has now released new PrecisA Monoclonal^TM antibodies targeting 23 proteins relevant to ovarian cancers.

Join us in supporting gynecologic cancer research with the markers featured below.

Here are the new monoclonals which you can find.

Order here online:

Anti-CLDN3 (AMAb91834, AMAb91835, AMAb91836)
Anti-CDX2 (AMAb91827, AMAb91828)
Anti-CALB2 (AMAb91812, AMAb91813, AMAb91814)
Anti-FOXL2 (AMAb91808, AMAb91809)
Anti-NAPSA (AMAb91825)
Anti-WFDC2 (AMAb91819, AMAb91821)
Anti-TFE3 (AMAb91798, AMAb91799)
Anti-NCAM1 (AMAb91807)
Anti-MCAM (AMAb91815)
Anti-TNFRSF8 (AMAb91800)
Anti-GPC3 (AMAb91803)
Anti-MLANA (AMAb91816, AMAb91817, AMAb91818)
Anti-CD99 (AMAb91823)
Anti-L1CAM (AMAb91829, AMAb91830)
Anti-CDKN1A (AMAb91832)
Anti-WT1 (AMAb91839, AMAb91840, AMAb91842)
Anti-FOXO1 (AMAb91844)
Anti-CD44 (AMAb91845, AMAb91846, AMAb91847, AMAb91848)
Anti-GSPT1 (AMAb91849, AMAb91851)

Atlas Antibodies develops and offers a wide selection of PrecisA Monoclonals and Triple A Polyclonals targeting:

Cancer Stem Cell , Mechanisms in Cancer, Glioma, Neuroendocrine Neoplasms, Oncology Biomarkers,
Epithelial-to-Mesenchymal Transition, GPCRs,
Colorectal, Breast and Ovarian cancer

Explore Primary Antibodies for Cancer Research

Figure 1: Claudin-3 is a prognostic marker for epithelial ovarian high-grade serous carcinoma (HGSC). The immunohistochemistry on ovarian cancer tissues using the Anti-CLDN3 monoclonal antibody (AMAb91835) reveals intense staining in high-grade (left) compared to low-grade (right) serous ovarian carcinoma.

Figure 2: CD44 is a prognostic endometrioid ovarian cancer (EC) marker. The immunohistochemistry on ovarian cancer tissues using the Anti-CD44 monoclonal antibody (AMAb91847) reveals positive staining in endometrioid (left) compared to papillary (right) ovarian carcinoma.

Figure 3: NAPSA is a diagnostic marker for ovarian clear cell carcinoma (CCC). Immunohistochemistry on ovarian cancer tissues using the Anti-NAPSA monoclonal antibody (AMAb91825). Positive staining is visible in brown in clear cell ovarian carcinoma (CCC, left) but not in high-grade serous ovarian carcinoma (HGSC, middle) and endometrial ovarian adenocarcinoma (EC, right).

Stay tuned for more details!